AZ’ Fasenra shows long-term efficacy in eosinophilic asthma
AstraZeneca has unveiled data from a Phase III extension trial highlighting the efficacy of biologic Fasenra as an add-on maintenance treatment in patients with severe eosinophilic asthma.
Read More
